9MW2821 Combined With Toripalimab Injection in Subjects With Local Advanced or Metastatic Urothelial Cancer
This is a phase Ib/II, open-label, multicenter clinical study to evaluate the safety, tolerability, efficacy, pharmacokinetics and immunogenicity of 9MW2821 combined with Toripalimab injection in subjects with local advanced or metastatic urothelial cancer.
Advanced Urothelial Carcinoma
DRUG: 9MW2821|DRUG: Toripalimab
incidence of AE/SAE, adverse event(AE) „ÄÅserious adverse event(SAE), Up to 24 months
Objective Response Rate, ORR, complete response (CR) or partial response (PR), Up to 24 months|Duration of Response, DOR, Time from the date of the first CR or PR to the earliest date of disease progression or death, Up to 24 months|Time To Response, TTR, Time from the date of first infusion to the date of CR or PR, Up to 24 months|Disease Control Rate, DCR, the percentage of subjects who experience CR, PR or stable disease (SD), Up to 24 months|Progression-Free Survival, PFS, Time from the date of first infusion to the earliest date of disease progression or death, Up to 24 months|Overall Survival, OS, Time from the date of first infusion to the date of death, Up to 24 months|Pharmacokinetics parameter, drug concentration of 9MW2821, Up to 12 months|Immunogenicity parameter, Anti-Drug Antibody (ADA) of 9MW2821, Up to 12 months
This is a phase Ib/II, open-label, multicenter clinical study to evaluate the safety, tolerability, efficacy, pharmacokinetics and immunogenicity of 9MW2821 combined with Toripalimab injection in subjects with local advanced or metastatic urothelial cancer.